Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines

Brian Godman, Claudia Wild, Alan Haycox

Research output: Contribution to journalEditorial

Abstract

Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.
LanguageEnglish
Pages1-3
Number of pages3
JournalGenerics and Biosimilars Initiative journal
Publication statusAccepted/In press - 17 Mar 2017

Fingerprint

Clinical Medicine
Protein-Tyrosine Kinases
Medicine
Costs and Cost Analysis
Costs
Neoplasms

Keywords

  • anti cancer medicines
  • medicine patents
  • tyrosine kinase inhibitors

Cite this

@article{84f0f4960d6444d599706fa92c6ee893,
title = "Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines",
abstract = "Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.",
keywords = "anti cancer medicines, medicine patents, tyrosine kinase inhibitors",
author = "Brian Godman and Claudia Wild and Alan Haycox",
year = "2017",
month = "3",
day = "17",
language = "English",
pages = "1--3",
journal = "Generics and Biosimilars Initiative journal",
issn = "2033-6403",

}

Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines. / Godman, Brian; Wild, Claudia; Haycox, Alan.

In: Generics and Biosimilars Initiative journal, 17.03.2017, p. 1-3.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Patent expiry and costs for anti-cancer medicines for clinical use

T2 - Generics and Biosimilars Initiative journal

AU - Godman, Brian

AU - Wild, Claudia

AU - Haycox, Alan

PY - 2017/3/17

Y1 - 2017/3/17

N2 - Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

AB - Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the patent expiry of (non-) tyrosine kinase inhibitors.

KW - anti cancer medicines

KW - medicine patents

KW - tyrosine kinase inhibitors

UR - http://gabi-journal.net/

M3 - Editorial

SP - 1

EP - 3

JO - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

ER -